{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T12:04:27Z","timestamp":1779192267156,"version":"3.51.4"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Immunology"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1016\/j.clim.2017.02.001","type":"journal-article","created":{"date-parts":[[2017,2,14]],"date-time":"2017-02-14T07:45:45Z","timestamp":1487058345000},"page":"47-53","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["Phase I trial of low-dose interleukin 2 therapy in patients with Wiskott-Aldrich syndrome"],"prefix":"10.1016","volume":"179","author":[{"given":"Soma","family":"Jyonouchi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brenda","family":"Gwafila","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lavesh A.","family":"Gwalani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chistopher","family":"Moertel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cecil","family":"Holbert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5596-8885","authenticated-orcid":false,"given":"Ji Young","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1122-8919","authenticated-orcid":false,"given":"Nathan","family":"Kobrinsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sumita","family":"Roy-Ghanta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jordan S.","family":"Orange","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clim.2017.02.001_bb0005","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/S0022-3476(05)82002-5","article-title":"A multiinstitutional survey of the Wiskott-Aldrich syndrome","volume":"125","author":"Sullivan","year":"1994","journal-title":"J. Pediatr."},{"key":"10.1016\/j.clim.2017.02.001_bb0010","doi-asserted-by":"crossref","first-page":"3231","DOI":"10.1182\/blood-2009-09-239087","article-title":"X-linked thrombocytopenia (XLT) due to WAS mutations: clinical characteristics, long-term outcome, and treatment options","volume":"115","author":"Albert","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clim.2017.02.001_bb0015","article-title":"Hematopoietic stem cell transplantation for X-linked thrombocytopenia with mutations in the WAS gene","author":"Oshima","year":"2014","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.clim.2017.02.001_bb0020","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.clim.2003.08.005","article-title":"An international study examining therapeutic options used in treatment of Wiskott-Aldrich syndrome","volume":"109","author":"Conley","year":"2003","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.clim.2017.02.001_bb0025","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1016\/S1286-4579(02)00038-2","article-title":"Human natural killer cell deficiencies and susceptibility to infection","volume":"4","author":"Orange","year":"2002","journal-title":"Microbes Infect."},{"key":"10.1016\/j.clim.2017.02.001_bb0030","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1182\/blood-2008-05-157354","article-title":"Human NK cells can control CMV infection in the absence of T cells","volume":"112","author":"Kuijpers","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clim.2017.02.001_bb0035","doi-asserted-by":"crossref","first-page":"5932","DOI":"10.1038\/onc.2008.267","article-title":"NK cells and cancer immunosurveillance","volume":"27","author":"Waldhauer","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.clim.2017.02.001_bb0040","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1007\/BF01957224","article-title":"Effect of interleukin 2 on intractable herpes virus infection and chronic eczematoid dermatitis in a patient with Wiskott-Aldrich syndrome","volume":"152","author":"Azuma","year":"1993","journal-title":"Eur. J. Pediatr."},{"key":"10.1016\/j.clim.2017.02.001_bb0045","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1007\/PL00008395","article-title":"Impaired interleukin-2 production in T-cells from a patient with Wiskott-Aldrich syndrome: basis of clinical effect of interleukin-2 replacement therapy","volume":"159","author":"Azuma","year":"2000","journal-title":"Eur. J. Pediatr."},{"key":"10.1016\/j.clim.2017.02.001_bb0050","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1016\/j.jaci.2005.09.006","article-title":"Defective nuclear translocation of nuclear factor of activated T cells and extracellular signal-regulated kinase underlies deficient IL-2 gene expression in Wiskott-Aldrich syndrome","volume":"116","author":"Cianferoni","year":"2005","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.clim.2017.02.001_bb0055","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1182\/blood-2003-07-2621","article-title":"Impaired natural and CD16-mediated NK cell cytotoxicity in patients with WAS and XLT: ability of IL-2 to correct NK cell functional defect","volume":"104","author":"Gismondi","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.clim.2017.02.001_bb0060","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1172\/JCI44862","article-title":"IL-2 induces a WAVE2-dependent pathway for actin reorganization that enables WASp-independent human NK cell function","volume":"121","author":"Orange","year":"2011","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.clim.2017.02.001_bb0065","doi-asserted-by":"crossref","first-page":"11351","DOI":"10.1073\/pnas.162376099","article-title":"Wiskott-Aldrich syndrome protein is required for NK cell cytotoxicity and colocalizes with actin to NK cell-activating immunologic synapses","volume":"99","author":"Orange","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.clim.2017.02.001_bb0070","doi-asserted-by":"crossref","first-page":"30636","DOI":"10.1038\/srep30636","article-title":"IL-2 in the tumor microenvironment is necessary for Wiskott-Aldrich syndrome protein deficient NK cells to respond to tumors in vivo","volume":"6","author":"Kritikou","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.clim.2017.02.001_bb0075","doi-asserted-by":"crossref","first-page":"5748","DOI":"10.1200\/JCO.2008.17.5448","volume":"26","author":"Atkins","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.clim.2017.02.001_bb0080","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1086\/342479","article-title":"Low-dose prolonged intermittent interleukin-2 adjuvant therapy: results of a randomized trial among human immunodeficiency virus-positive patients with advanced immune impairment","volume":"186","author":"Marchetti","year":"2002","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.clim.2017.02.001_bb0085","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1056\/NEJMoa1105143","article-title":"Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis","volume":"365","author":"Saadoun","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clim.2017.02.001_bb0090","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S2213-8587(13)70113-X","article-title":"Low-dose interleukin 2 in patients with type 1 diabetes: a phase 1\/2 randomised, double-blind, placebo-controlled trial","volume":"1","author":"Hartemann","year":"2013","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.clim.2017.02.001_bb0095","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1001\/jamadermatol.2014.504","article-title":"Effects of low-dose recombinant interleukin 2 to promote T-regulatory cells in alopecia areata","volume":"150","author":"Castela","year":"2014","journal-title":"JAMA Dermatol."},{"key":"10.1016\/j.clim.2017.02.001_bb0100","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1093\/jnci\/djp079","article-title":"Dose escalation methods in phase I cancer clinical trials","volume":"101","author":"Le Tourneau","year":"2009","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.clim.2017.02.001_bb0105","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.bbmt.2008.10.007","article-title":"Wiskott-Aldrich syndrome: diagnosis, clinical and laboratory manifestations, and treatment","volume":"15","author":"Ochs","year":"2009","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.clim.2017.02.001_bb0110","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/0002-9343(90)90343-C","article-title":"Thrombocytopenia during immunotherapy with interleukin-2 by constant infusion","volume":"89","author":"Paciucci","year":"1990","journal-title":"Am. J. Med."},{"key":"10.1016\/j.clim.2017.02.001_bb0115","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s002770100340","article-title":"Severe Evans's syndrome secondary to interleukin-2 therapy: treatment with chimeric monoclonal anti-CD20 antibody","volume":"80","author":"Abdel-Raheem","year":"2001","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.clim.2017.02.001_bb0120","article-title":"Low-dose interleukin-2 selectively corrects regulatory T cell defects in patients with systemic lupus erythematosus","author":"von Spee-Mayer","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.clim.2017.02.001_bb0125","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1056\/NEJMoa1108188","article-title":"Interleukin-2 and regulatory T cells in graft-versus-host disease","volume":"365","author":"Koreth","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clim.2017.02.001_bb0130","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1158\/1078-0432.CCR-13-3205","article-title":"Ultra low-dose IL-2 for GVHD prophylaxis after allogeneic hematopoietic stem cell transplantation mediates expansion of regulatory T cells without diminishing antiviral and antileukemic activity","volume":"20","author":"Kennedy-Nasser","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.clim.2017.02.001_bb0135","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1084\/jem.20061338","article-title":"The Wiskott-Aldrich syndrome protein is required for the function of CD4(+)CD25(+)Foxp3(+) regulatory T cells","volume":"204","author":"Maillard","year":"2007","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.clim.2017.02.001_bb0140","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1084\/jem.20061334","article-title":"WASP regulates suppressor activity of human and murine CD4(+)CD25(+)FOXP3(+) natural regulatory T cells","volume":"204","author":"Marangoni","year":"2007","journal-title":"J. Exp. Med."}],"container-title":["Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661616303928?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661616303928?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,4]],"date-time":"2018-09-04T05:52:43Z","timestamp":1536040363000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521661616303928"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":28,"alternative-id":["S1521661616303928"],"URL":"https:\/\/doi.org\/10.1016\/j.clim.2017.02.001","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.727343869.793532213","asserted-by":"object"}]},"ISSN":["1521-6616"],"issn-type":[{"value":"1521-6616","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase I trial of low-dose interleukin 2 therapy in patients with Wiskott-Aldrich syndrome","name":"articletitle","label":"Article Title"},{"value":"Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clim.2017.02.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}